After 150 days of the COVID-19 pandemic, here are the best- and worst-performing stocks
Provided by Dow Jones
After 150 days of the COVID-19 -2-
Provided by Dow Jones
Pfizer to Manufacture Gilead's Remdesivir for Covid-19 Treatment — Update
Provided by Dow Jones
Pfizer to Manufacture Gilead's Remdesivir for Covid-19 Treatment
Provided by Dow Jones
Pfizer, Gilead in Agreement to Manufacture Remdesivir for Covid-19
Provided by Dow Jones
Pfizer to help manufacture Gilead's remdesivir
Provided by Dow Jones
Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19
Provided by Business Wire
Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
Provided by Business Wire
Bristol-Myers, Pfizer stocks rise on blood-thinner patent win
Provided by Dow Jones
Covid-19 Vaccine Makers Signal Prices
Provided by Dow Jones
